ARTICLE | Clinical News

FDA approves La Jolla's distributive shock therapy

December 22, 2017 5:04 PM UTC

FDA approved Giapreza angiotensin II (formerly LJPC-501) from La Jolla Pharmaceutical Co. (NASDAQ:LJPC) to increase blood pressure in adults with septic or other distributive shock.

The company plans to launch the renin-angiotensin system peptide agonist in March, but did not disclose pricing information...

BCIQ Company Profiles

La Jolla Pharmaceutical Co.